Iowa Digestive Disease Center

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)4 trials
• Crohn's disease2 trials
• Ulcerative colitis2 trials

Phase

• Phase 35 trials
• Phase 22 trials
• Phase 41 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Abivax S.A.1 trial
• Boehringer Ingelheim1 trial
• Celgene1 trial
• Eli Lilly and Company1 trial
• Kowa Research Institute, Inc.1 trial
• and 3 more

Running trials

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Abivax S.A.· Source

• Active, not recruiting

  Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT04822181· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting

Closed trials

• Completed

  Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

  NCT05327127· Phase 2· Kowa Research Institute, Inc.· Source

• Completed

  A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

  NCT04809363· Phase 4· Takeda· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Terminated

  Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

  NCT03440372· Phase 3· Celgene· Source